🇺🇸

Corporate Governance

US SEC Filing Intelligence · 148 digests

· daily

US Executive Compensation Proxy SEC Filings — May 14, 2026

Across 11 DEF 14A proxy statements filed around May 14, 2026, dominant themes include director elections (9/11 filings), advisory votes on executive compensation (6/11), auditor ratifications (7/11), and equity incentive plan expansions (2/11), signaling standard proxy season activities amid governance focus. EDAP TMS SA stands out with robust YoY HIFU revenue growth to record levels and new product launches, contrasting neutral/mixed sentiments elsewhere; no widespread period-over-period financial trends evident beyond EDAP's positive revenue and Signet's multi-year pay-vs-performance disclosures spanning FY2022-2026. High materiality events include Origin Materials' liquidation plan (10/10) and Mountain Lake's merger risks (9/10), implying bearish portfolio pressure in materials/SPAC segments. Neutral sentiment prevails (6/11), with mixed (1/11) and negative (2/11) outliers highlighting governance risks like Myomo's declassification proposal. Capital allocation leans toward equity incentives for talent retention, with no dividend/buyback mentions; upcoming June 2026 meetings form a dense catalyst calendar for votes on comp and plans.

11 high priority 11 total filings
· daily

US Executive Officer Management Changes SEC — May 14, 2026

Across 24 filings in the USA Executive & Director Changes stream (May 14, 2026), dominant themes include orderly C-suite retirements with named successors in insurance (RenaissanceRe CFO/CPO retire Dec 2026/Jan 2027, Selective CIO retires June 2026), sudden separations without detailed reasons (CSX CTO immediate exit, Ocugen CMO May 8, Xponential COO May 13), and positive board appointments in financials/biotech (AIG independent director June 1, Corbus pharma veteran ahead of ASCO). Capital allocation remains bullish with new $5B CSX share repurchase (atop $989M remaining) and $3B KeyCorp program replacing $1B prior ($280M left), signaling management confidence amid stable dividends. Annual meetings showed strong approvals but pockets of opposition (e.g., CSX director votes 299M against, Fulgent 6M withheld on director). NeoVolta outlier with 262% 9-mo revenue growth to $13.3M despite flat Q3, gross margins +20pp to 46%; no broad YoY/QoQ deterioration but diverse sectors limit portfolio trends. Implications: Succession planning enhances stability (positive for insurers), abrupt exits flag monitoring (COO/CTO roles), buybacks boost returns in transport/banks.

24 high priority 24 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 14, 2026

The 24 filings reveal a surge in boardroom stability through annual meetings (Fulgent, CSX, Cushman, DMC Global, Delcath, InfuSystem) with director elections mostly passing despite notable opposition in Fulgent (up to 6M withheld for Groves) and CSX (299M against Zillmer). Executive transitions dominate, with orderly retirements and appointments (Selective CIO to interim, RenaissanceRe CFO/CPO to internal successors Jan 2027, AIG independent dir Jun 1, Standex CFO promo), but abrupt separations (CSX EVP immediate, Ocugen CMO May 8, Xponential COO May 13) raise flags. Capital allocation shines with CSX's $5B buyback atop $989M remaining and KeyCorp's $3B program replacing $1B ($280M left) plus $0.205 dividend; equity plans approved widely (Fulgent 2M+1.5M shares, Cushman 12M+, Delcath +1.8M). NeoVolta outlier with Q3 revenue flat YoY at $2M but 9-mo +262% to $13.3M, margins 46% vs 26% YoY despite wider $3M loss. Portfolio trends: Positive sentiments in 7/24 (e.g., insurance, fitness), mixed/neutral elsewhere; no broad insider selling but appointments signal conviction. Implications: Bullish for capital returns in financials/transport, monitor governance dissent and transitions for execution risks.

24 high priority 24 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 13, 2026

Across 41 SEC filings on USA Board Room Changes from May 13, 2026, the dominant theme is high C-suite and board turnover, with 12 CEO/CFO/president departures or transitions (e.g., HF Sinclair CFO termination, Power Solutions CEO resignation, Rent the Runway CEO step-down) amid neutral-to-negative sentiment, signaling potential instability in energy, pharma, and tech sectors. Annual shareholder meetings (15 filings) overwhelmingly passed director elections, auditor ratifications, and equity plans with 90-99% support (e.g., Vertex 94-99%, MDU >90%), reinforcing governance stability. Period-over-period trends show mixed financials: revenue growth in Doximity (+13% FY2026 YoY to $644.9M) and cash runway extensions (Tango to 2028, Zenas to Q2 2029), but margin compression in consumer names (Jack in the Box Restaurant-Level Margin -320 bps YoY to 16.4%) and widening losses in biopharma (Tango net loss +14% to $45.5M, Zenas +141% to $81M). Capital allocation leans bullish with Hanover's $700M buyback authorization (+$637M vs prior remainder), Coeur Mining's inaugural $0.02/share dividend, and LTIP expansions (e.g., MDU +6.56M shares). Forward-looking catalysts cluster in pharma (e.g., Zenas BLA Q2 2026, Tango data readouts 2026), while leadership promotions signal continuity (e.g., Toll Brothers EVP to President). Portfolio implication: Favor stable boards with buybacks/dividends; avoid high-turnover firms until interim stability proven.

41 high priority 41 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 12, 2026

Across 12 DEF 14A filings dated May 12, 2026, a dominant theme is clustered June 2026 shareholder meetings (10/12 between June 2-25) for director elections (11/12), auditor ratifications (9/12), say-on-pay votes (4/12), and advisory agreement approvals amid control changes or M&A (5/12 funds/ETFs). Period-over-period trends reveal stark contrasts: NVIDIA's explosive FY2026 revenue +65% YoY to $215.9B and EPS +67% to $4.90 outpace peers, while CarMax EPS plunged -47.7% YoY to $1.68 amid sales declines and impairments, Apogee sales edged +3% YoY but op margin contracted -270 bps to 6.0%, and funds show no financial declines but advisor disruptions. Mixed sentiment prevails (4/12 mixed), with high materiality in growth outliers (NVIDIA, CarMax 9/10) and fund transitions (MFS, Tavia 9/10). No insider trading or capital allocation shifts noted across filings, but director ownership at Dyadic (20.9%) signals alignment. Market implications include governance catalysts for volatility, potential continuity post-approvals boosting stability in funds/tech, and relative outperformance opportunities in high-growth names like NVDA versus cyclical decliners like KMX/APOG. Portfolio-level pattern: Margin compression in 3/4 detailed financials (avg -150 bps) despite uneven revenue growth, highlighting cost pressures amid transitions.

12 high priority 12 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 11, 2026

Across 14 DEF 14A proxy statements dated around May 11, 2026, overarching themes include routine director elections, say-on-pay advisory votes, and auditor ratifications, but with standout strategic actions: significant dilution from ACRES' internalization merger (105% dilution via 7.5M new shares), Coursera's Udemy merger boosting scale to $1.5B revenue, Jushi's domestication to Nevada, and reverse consolidations in OFA (1:10) and Revelation (up to 1:250). Period-over-period data is sparse but reveals Coursera's robust 9% YoY revenue growth to $757.5M and record $78.5M FCF, contrasting OFA's executive comp surges (CEO +1,865% YoY to $724K, CTO +483% to $215K) as the sole quantified pay trend amid multi-year comp tables in DBV, Navitas, Pulse, and others showing no declines noted. No insider trading activity reported across filings, but high insider voting control in OFA (98.68%) raises governance flags. Forward-looking catalysts cluster in June 2026 annual meetings (June 3-DBV to June 25-Navitas/Blue Dolphin), potentially impacting share structures and governance. Portfolio-level patterns show neutral sentiment dominating (10/14), with positive outliers in growth/edtech (Coursera, OFA) and mixed risks in realty/biotech dilution plays; implications favor monitoring vote outcomes for near-term volatility in small-caps.

14 high priority 14 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 11, 2026

Across 38 US SEC filings on board room changes from May 11, 2026, a surge in C-suite transitions dominates, with 14 CFO/CAO changes (e.g., SolarEdge, Nature’s Sunshine, Koppers), 8 CEO/Chair shifts (e.g., Faraday Future, PagerDuty, American Cannabis), and numerous board resignations/appointments, signaling strategic realignments amid AI/EV growth and spin-offs. Annual meetings (e.g., UPS, Alcoa, Charles River) showed overwhelming approvals for directors, compensation plans, and auditors (avg 90%+ FOR votes), with minor opposition in select cases like CarParts.com (25% withheld for one director). Positive forward-looking catalysts include Faraday Future's 68 EAI robots shipped (positive gross margins, targeting 200 by June 2026 end, 1,000+ cumulative), Resideo's ADI spin-off (Q3-Q4 2026, $4.8B FY2025 rev, 6.6% EBITDA margin), and PagerDuty's reaffirmed FY2027 guidance ($488.5-496.5M rev). Neutral sentiment prevails (60% of filings), but positive tones in tech/EV/mining (e.g., Hycroft, Uber) contrast mixed in retail/transport; no widespread YoY declines noted, though ADI's $261M net loss flags spin-off risks. Portfolio implication: Leadership refreshes enhance conviction in growth sectors, but monitor interim gaps and proxy contests (e.g., Victoria's Secret). Overall, bullish for AI/robotics plays, neutral stability elsewhere.

38 high priority 38 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 08, 2026

Across 15 DEF 14A proxy statements filed around May 8, 2026, the dominant theme is routine annual shareholder meetings in June 2026 focused on director elections, auditor ratifications, and advisory votes on executive compensation, with 12/15 featuring board elections or renewals signaling governance continuity. Period-over-period financial trends are sparse but highlight resilience in apparel (PVH Corp revenue growth amid macro challenges, 8.8% non-GAAP margins despite -80 bps tariff hit, $560M shareholder returns) contrasted by edtech weakness (Skillsoft FY2026 revenue -3% YoY to $513M, net loss widened to $140M). Mixed sentiments prevail in 3 filings, driven by SPAC extension risks (Rising Dragon high prior redemptions of 5.7M shares at $10.63 vs $7.63 market price) and fund strategy shifts (John Hancock non-diversified status increases concentration risk). Capital allocation leans positive with PVH's repurchases and Criteo's buyback authorizations, while forward-looking catalysts cluster in mid-June meetings for potential equity plan approvals and governance changes like board declassifications (NRC, nCino). No widespread insider trading activity noted, but sponsor deposits in Rising Dragon indicate management conviction. Overall, low materiality (avg 6.5/10) suggests stable but unexciting proxy season, with alpha in governance upgrades and SPAC extension outcomes.

15 high priority 15 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 07, 2026

Across 15 DEF 14A filings dated May 7, 2026, proxy season reveals a cluster of 12 annual/special meetings scheduled June 16-23, 2026, primarily for routine director elections (14/15 filings), say-on-pay advisory votes (9/15), auditor ratifications (9/15), and equity incentive plan approvals/amendments (4/15), signaling standard governance focus with no widespread financial declines disclosed. High insider ownership stands out in Capstone Holding (39.29% by directors/officers, CEO 21.12%/26.77% voting), indicating strong alignment, while positive transformation narratives in Designer Brands (inventory productivity, profitability gains despite tariffs) and Okta (AI agent era shift, board refresh) contrast neutral/mixed sentiment elsewhere. No explicit YoY/QoQ revenue or margin declines noted across filings, but governance risks emerge in Wave Life Sciences' redomiciliation (75% approval threshold, shareholder rights changes) and equity dilutions in CXApp/SurgePays (20%+ share issuances). Fund-heavy filings (6/15) show trustee elections post-acquisitions with continuity assurances. Portfolio implication: monitor June vote outcomes for governance catalysts, favoring high-ownership names like Capstone for conviction plays amid low-materiality routines.

15 high priority 15 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 06, 2026

Across 11 DEF 14A proxy statements, overarching themes include routine director elections (10/11 filings), advisory say-on-pay votes on 2025/2026 executive compensation (7/11), auditor ratifications (8/11), and governance enhancements like officer exculpation amendments and equity plan expansions, with all AGMs clustered in June 2026. Period-over-period trends are sparse but highlight exceptional performance at Williams Sonoma (FY2025 record $8.84 EPS, 18.1% op margin, 3.5% comp brand revenue growth, 241% 3yr TSR vs peer 22%) and BJ's Wholesale (100% director attendance, zero insider policy violations), contrasting Lithium Americas' mixed lithium price declines to June 2025 lows followed by H2 recovery amid Thacker Pass funding ($905.6M cash, 93% engineering complete). No widespread margin compression or revenue declines noted; instead, positive governance and project milestones dominate. Portfolio-level patterns show strong consumer/retail conviction (2/11 with positive sentiment), routine fund/BDC filings (4/11 neutral), and dilution risks from equity plans (e.g., Fluent +52% shares). Market implications: High approval odds for proposals boost stability, but watch comp votes and virtual AGMs for shareholder sentiment signals ahead of summer catalysts.

11 high priority 11 total filings
· daily

US Executive Officer Management Changes SEC — May 06, 2026

Across 34 filings in the USA Executive & Director Changes stream (May 6, 2026), leadership transitions dominate with 18 CEO/CFO/COO promotions or appointments (e.g., Orrstown, General Mills, Birchtech), 10 departures/retirements (e.g., Anavex CEO, Energy Recovery CEO/CFO), and 6 annual meetings with strong director election support (avg 95%+ for/approval). Period-over-period trends show mixed financials where disclosed: Energy Recovery revenue +20% YoY but gross margins -2750 bps to 27.8%; eHealth revenue -22% YoY but Medicare margins +700 bps to 41%; no broad insider trading but capital allocation positives like Energy Recovery's $25M buyback and Carvana's 1:5 split. Positive sentiment in 12/34 (35%) centers on experienced hires/promotions enhancing strategy (e.g., Hamilton Insurance, Wiley AI focus), while mixed/negative in 7/34 flag risks from sudden exits (Regenerex CFO termination, Anavex CEO departure with 10-Q delay). Portfolio-level pattern: orderly transitions signal continuity in financials/insurance (e.g., Orrstown, RenaissRe), but biotech/healthcare shows churn (Anavex, Bionano, Actuate with going concern). Implications: Bullish for stable firms with internal promotions; monitor biotech for disruption risks amid M&A/innovation catalysts.

34 high priority 34 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 06, 2026

Across 34 filings from May 6, 2026, USA boardroom changes reveal high executive turnover with 12 CEO/CFO transitions (7 appointments, 5 departures), predominantly neutral sentiment (18/34) but tilting positive in financials/insurance (e.g., 95%+ AGM approvals in 6 cases). Period-over-period trends show mixed financial health: revenue growth in 4 firms (Energy Recovery +20% YoY, OEM +65%; eHealth Medicare margins +700bps despite -22% rev; Flutter FY25 +17%) contrasted by sharp declines (Energy Recovery gross margins -2750bps, eHealth net loss widening). Critical developments include sudden CFO terminations/suspensions (Regenerex, Bright Mountain) and interim leadership in biotechs (Anavex, Bionano), signaling potential governance risks amid 3 10-Q extensions/delays. Portfolio-level patterns: Planned retirements/successions (8 cases) outnumber contentious exits (4), with strong shareholder support at AGMs (avg 95%+ approval rates); insurance/financial sectors show board strengthening via experienced adds, while biotechs face leadership voids amid cash concerns. Capital allocation leans retention-focused (e.g., Energy Recovery $25M buyback, comp hikes), but M&A/integration ties (Flora, International Endeavors) flag strategic shifts. Implications: Opportunities in stable transitions, risks in interim-heavy biotechs.

34 high priority 34 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 05, 2026

Across 12 DEF 14A proxy filings dated around May 5, 2026, overarching themes include routine annual meetings for director elections (9/12), auditor ratifications (10/12), say-on-pay advisory votes (5/12), and equity incentive plan approvals, alongside special actions like share increases (Orgenesis, FibroBiologics), SPAC deadline extensions (Range Capital), reverse stock splits (Beyond Air), and reincorporations (Sonoma). Key period-over-period trends: CrowdStrike's FY2026 revenue +22% YoY to $4.81B, ARR +24% YoY to $5.25B, FCF margin 26%; FONAR exec comp down 21% YoY for CEO to $295k while flat for another; Range Capital trust +5.6% to $121.9M from post-IPO $115.6M. Critical developments: delisting risks (Beyond Air), dilution proposals (4/12 filings), and strong governance signals (Workday). Market implications: heightened dilution risks in biotechs/SPACs signal bearish near-term pressure, while SaaS leaders like CrowdStrike show portfolio-level growth outperformance; neutral sentiment dominates (8/12), but vote outcomes could drive volatility ahead of summer meetings.

12 high priority 12 total filings
· daily

US Executive Officer Management Changes SEC — May 05, 2026

Across 36 filings in the USA Executive & Director Changes stream, a dominant theme is high executive turnover, particularly in finance roles (CFOs, controllers, accounting officers in 12 companies including Atlantic American, Kimberly-Clark, Core Scientific, CF Industries, Genesco, Portillo's), with 18 appointments and 14 departures, often neutral but featuring experienced hires signaling continuity. Embedded Q1/FY2026 earnings show mixed revenue trends (avg +3.5% YoY across 15 reporting firms, but declines in 7 like Energizer -3%, FTC Solar -17%, Primoris -5.4%), offset by margin expansions (e.g., Energizer +360bps, Emerson +320bps) and reaffirmed/raised guidance in 10 cases. Positive sentiments dominate leadership adds (e.g., Integra, iAnthus, CF Industries), while negatives cluster around disputes (B&G Foods). Portfolio-level: Margin resilience amid soft volumes; capital returns strong ($500M Klaviyo buyback, $2.2B Emerson). Implications: Opportunities in experienced leadership turnarounds, risks in finance churn; watch catalysts like earnings calls.

36 high priority 36 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 05, 2026

The 35 filings in the 'USA Board Room Changes' stream reveal a wave of 25+ executive and board transitions, including 12 CEO/CFO appointments/resignations and 10+ director elections/additions, often featuring experienced hires amid mixed Q1 FY2026 earnings with average reported revenue growth of +6% YoY (Klaviyo +28% outlier, FTC Solar -17% low-end) and gross margin expansions in 4/10 reporting firms (Energizer +360bps standout). Declines in volumes/sales hit cyclical sectors (Energizer batteries -6.1%, Primoris Energy -13.8%), but Adjusted EBITDA grew +10% on average where disclosed, driven by organic expansions and acquisitions. Guidance was raised/reaffirmed in 8/12 cases (e.g., AdaptHealth revenue to $3.45-3.52B, Klaviyo to $1.514-1.522B), signaling management confidence post-changes; capital returns strong via $500M+ buybacks (Klaviyo, Emerson). Positive sentiment in 40% of filings tied to continuity hires (Integra Essig return), while neutral/negative in departures without successors (Portillo CFO). Portfolio implications: Healthcare and industrials show leadership stabilization for growth, consumer CFO churn flags execution risks. Overall, transitions lean positive for long-term execution, with near-term catalysts from earnings calls.

35 high priority 35 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 04, 2026

Across these 10 DEF 14A proxy statements for US companies, a dominant theme is preparation for mid-June 2026 annual meetings, with 9/10 virtual and focused on routine governance items like director elections (all 10), say-on-pay advisory votes (8/10), and auditor ratifications (10/10), signaling stable board continuity amid executive compensation scrutiny. Financial highlights are sparse but reveal stark contrasts: National Vision Holdings stands out with FY2025 revenue +9.0% YoY to $1,987.5M, Adjusted Op Income +56.5% YoY to $102.5M (margin +5.2pp to 8.8%), and Adj EPS +53.8% YoY to $0.80, while STAAR Surgical reports a challenging FY2025 with slower growth and merger rejection but positive 2026 momentum from EVO+ exceeding expectations in China. Veeva Systems signals strong shareholder alignment via $2B buyback and engagement with 40% of shares, contrasting dilution risks in Wellgistics (blank check preferred) and Xos (plan expansion + note conversions >20% shares). Mixed/neutral sentiments prevail (7 neutral, 2 positive, 2 mixed), with no widespread insider trading or capital allocation shifts beyond Veeva's repurchase; portfolio-level trends show healthcare/tech firms prioritizing equity incentives amid governance enhancements like Helios' clawback policy. Market implications include low volatility from routine votes but alpha from outliers like National Vision's growth and STAAR's turnaround, with clustered catalysts in June 2026.

10 high priority 10 total filings
· daily

US Executive Officer Management Changes SEC — May 04, 2026

Across 45 filings in the USA Executive & Director Changes stream (33 new), a wave of 20+ CEO/CFO/executive transitions dominates, including 8 retirements/planned departures (e.g., Publix Executive Chairman, Occidental CEO, Exxon CAO, Pool Corp CEO, Adeia CEO) and 15+ appointments/promotions (e.g., Aura CEO, Hercules President/CFO, Edwards Lifesciences CFO from Viatris), signaling proactive leadership refreshes amid sector pressures. Financial trends where reported show mixed results: BDCs like New Mountain (NII flat YoY at $0.32/share, NAV -5% QoQ to $10.92) and Great Elm (NII +13% QoQ to $0.36/share but NAV -4% QoQ to $7.74) highlight portfolio volatility; Sonos Q2 rev +8% YoY to $282M with first positive EBITDA in 4 years; Pinterest Q1 rev +18% YoY to $1.008B but net loss widened to $74M. Capital allocation remains shareholder-friendly with repurchases (New Mountain $66M YTD +$50M auth, Great Elm 1% shares at 36% NAV discount, Intuitive $5B program increase) and dividends (Great Elm $0.25/share Q2, 18% yield). Positive sentiments in 60% of filings (e.g., hires with deep expertise), but mixed/neutral in departures; biotech hires (Aura, Pasithea, Tivic) tie to trial catalysts. Portfolio-level: Margin stability in consumer/tech offset by BDC NAV erosion; energy/retail transitions orderly. Implications: Opportunities in growth-oriented hires (biotech, semis), risks in BDC volatility and sudden CFO churn (5 cases).

45 high priority 45 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 04, 2026

Across 45 filings on USA Board Room Changes from May 4, 2026, a dominant theme is C-suite and board transitions, with 18 CEO/President/CFO changes (9 appointments, 9 departures/retirements), 12 new director additions, and 8 annual meetings showing strong shareholder approval (avg 95%+ for directors/say-on-pay). Period-over-period trends reveal mixed financial health: revenue growth in 4/7 reporters (Sonos +8% YoY Q2, Pinterest +18% YoY Q1 avg ARPU +6%, GECC NII +13% QoQ Q1, New Mountain NII flat YoY), but NAV declines in BDCs (GECC -4% QoQ to $7.74, New Mountain -5% to $10.92) and losses (Sonos Q2 GAAP net loss $29M improved YoY, Pinterest Q1 loss widened to $74M). Capital allocation remains shareholder-friendly with $5B Intuitive Surgical buyback increase, $2B Pinterest repurchases, GECC $57.5M note calls/$0.5M share buyback, New Mountain $66M YTD repurchases +$50M auth. Positive biotech appointments (Aura, Tivic, Pasithea) bolster trials, while planned energy transitions (Occidental, Exxon, Publix) signal continuity. Implications: Opportunities in experienced leadership hires amid churn, risks from interim roles and NAV pressure in BDCs/fintech.

45 high priority 45 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 01, 2026

Across 10 DEF 14A proxy statements filed around May 1, 2026, a dominant theme is robust corporate governance with high director independence (>90% in cases like Dollar Tree), 100% independent committees, clawback policies, no option repricing, and hedging/pledging restrictions, signaling strong board oversight amid executive compensation scrutiny. Period-over-period trends reveal pockets of robust growth, notably Dick's Sporting Goods' net sales surging 28.1% YoY to $17.22B driven by Foot Locker acquisition, Pure Storage's (Everpure) FY26 revenue up 16% YoY to $3.7B with first $1B quarter and $1.9B subscription ARR, contrasting neutral sentiment elsewhere; Citi Trends shows modest audit fee growth of 4.1% YoY to $755K. All filings feature advisory votes on NEO compensation with boards recommending approval, highlighting pay-vs-performance disclosures spanning 2021-2026. Upcoming virtual AGMs clustered June 10-23, 2026, serve as key catalysts for shareholder sentiment on comp and governance. Portfolio-level patterns indicate retail/tech resilience via M&A and subscriptions, but outliers like AquaBounty's reverse split proposal and going concern risks flag distress in biotech/mining. Market implications favor governance leaders for lower volatility, with growth outliers offering upside amid neutral backdrops.

10 high priority 10 total filings
· daily

US Executive Officer Management Changes SEC — May 01, 2026

Across 44 filings in the USA Executive & Director Changes stream (40 new), a dominant theme is strong shareholder support at 2026 AGMs, with 12+ companies (e.g., Sonic Automotive 85-95% director approvals, Truist 89% quorum, TechnipFMC 98%+ proposals) signaling board stability and approval of comp/equity plans. CFO and key exec churn is evident in 12 cases (e.g., Worksport, Cisco CAO, KB Home CFO, Natural Alternatives CFO resignations), mostly neutral without disagreements, often with internal promotions or experienced replacements. Period-over-period trends show mixed financials: Perella Weinberg revenues -30% YoY to $148.9M with comp ratio +12pts to 82%; Universal Logistics revenues -4% YoY to $367.6M, swing to $(3.5M) net loss; BioRestorative exec comp +83% CEO YoY to $2.4M. Positive appointments (e.g., Carter’s new CEO Sharon Price John, Deere CFO Brent Norwood) and M&A integrations (Stock Yards adding branches/CEO) highlight growth strategies. Capital allocation remains shareholder-friendly with dividends (Perella $0.07, Universal $0.105). Portfolio implications: Monitor finance role turnover for small/mid-caps as potential early warning; bullish on industrials/autos with expert board adds.

44 high priority 44 total filings